Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stroke prophylaxis with Apixaban in CKD stage 5 patients with atrial fibrillation (SACK)
2022-501600-10-00Phase 3Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3 trial of apixaban in Atrial fibrillation (AFib), atrial flutter (AFL), chronic kidney disease (CKD) and 1 more, sponsored by Karolinska University Hospital. Primary endpoint: Ischemic stroke and systemic embolism (composite). Planned start Nov 2022; status: authorised.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2022-501600-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501600-10-00.